Inactive Instrument

Standard BioTools Inc.

SLGC

US83444K1051

Biotechnology & Medical Research

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

February 04, 2022 at 08:00 am

SomaLogic, Inc. provided revenue guidance for the year 2022. Management projects 2022 revenue of approximately $105 million to $110 million.

Latest news about Standard BioTools Inc.

Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P Global BMI Index	01-10	CI
Standard BioTools Inc.(NasdaqGM:SLGC) dropped from S&P TMI Index	01-10	CI
Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023	01-08	CI
Declaration of Voting Results by SomaLogic Inc	01-05	CI
Declaration of Voting Results by SomaLogic Inc	01-05	CI
Declaration of Voting Results by SomaLogic Inc	01-05	CI
Declaration of Voting Results by SomaLogic Inc	01-05	CI
Declaration of Voting Results by SomaLogic Inc	01-05	CI
Standard BioTools Says Merger With SomaLogic Completed	01-05	MT
SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger	01-05	MT
SomaLogic, Inc.(NasdaqGM:SLGC) dropped from NASDAQ Composite Index	01-05	CI
Madryn Asset Addresses SomaLogic?s Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools	01-04	CI
Madryn Asset Management, LP Sends an Email to Stockholders in Connection with Somalogic, Inc.?s Special Meeting of Stockholders	01-04	CI
Madryn Asset Management Sent a Letter to the Delaware Court of Chancery	01-03	CI
Madryn Asset Provides Information to the Shareholders	01-03	CI
Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioTools	01-03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	01-03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	01-03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	01-03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	01-03	CI
Jason Ryan Issues a Letter to Shareholders of SomaLogic Inc	01-03	CI
SomaLogic Sends an Open Letter to Shareholders	01-02	CI
SomaLogic Sends an Open Letter to Shareholders	01-02	CI
SomaLogic Sends an Open Letter to Shareholders	01-02	CI
SomaLogic Sends an Open Letter to Shareholders	01-02	CI

SomaLogic, Inc. is a commercial-stage proteomics company. The Company has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. It offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research

Standard BioTools Inc.

Equities

SLGC

US83444K1051

Biotechnology & Medical Research

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

Latest news about Standard BioTools Inc.

Chart Standard BioTools Inc.

Company Profile

Sector Other Biotechnology & Medical Research